Immix Biopharma, Inc.

NASDAQ:IMMX

1.58 (USD) • At close November 4, 2024
Bedrijfsnaam Immix Biopharma, Inc.
Symbool IMMX
Munteenheid USD
Prijs 1.58
Beurswaarde 43,371,758
Dividendpercentage 0%
52-weken bereik 1.26 - 7.75
Industrie Biotechnology
Sector Healthcare
CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Website https://www.immixbio.com

An error occurred while fetching data.

Over Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for

Vergelijkbare Aandelen

Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

AVTX

13.54 USD

FSD Pharma Inc. logo

FSD Pharma Inc.

HUGE

0.09 USD

T2 Biosystems, Inc. logo

T2 Biosystems, Inc.

TTOO

0.8 USD

ARCA biopharma, Inc. logo

ARCA biopharma, Inc.

ABIO

28.8 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)